Speaking to CNBC on January 13, Ari Wald, Head of Technical Analysis at Oppenheimer, said U.S. equity markets still appear to be in a healthy bull cycle, based on technical signals rather than fundamentals. Wald said that Oppenheimer’s 2026 target for the S&P 500 is 7,700, reflecting expectations for further upside. He acknowledged that the market is now in a later stage of the cycle, which typically raises concerns about a peak. However, he emphasized that the typical warning signs of a market top are not yet visible.
Interestingly, Wald believes market breadth is improving, which is a positive sign. He argued that smaller stocks, particularly the Russell 2000, are breaking above long-standing resistance levels, suggesting that gains are spreading beyond just large-cap stocks. Wald thinks that the market’s gains are not limited to just a few large technology stocks. While he still views technology as the long-term leader, he said the current phase is characterized by broader participation across sectors and regions.
As equity markets are expected to inch higher, Morgan Stanley Research also recently shared similar views and recommended an overweight position in stocks, particularly in US assets.
According to a Morgan Stanley note from November, U.S. equities should outperform global peers in 2026, with the S&P 500 increasing 14% to 7,800 in the next 12 months, compared with expected gains of 7% for Japan’s TOPIX and 4% for the MSCI Europe. U.S. earnings and revenue growth are positioned to benefit from several factors, including a market-friendly policy mix, interest-rate cuts by the Federal Reserve, and a $129 billion cut in corporate tax bills through 2026 and 2027 under the One Big Beautiful Act.
“There will be some bumps along the way, but we believe that the bull market is intact,” Serena Tang, Morgan Stanley’s Chief Global Cross-Asset Strategist, said.
In such a supportive environment, one strategy is to consider U.S. stocks with high revenue growth by targeting companies with rapidly expanding top-line sales, often in tech, biotech, or other emerging sectors. Investors prioritize future potential over current profits, betting on compounding returns as these firms scale.
With this in mind, let’s take a look at the 13 Best Revenue Growth Stocks to Buy Right Now.
Our Methodology
To curate the list of 13 best revenue growth stocks to buy right now, we used the Stock Analysis Screener and Insider Monkey’s Q3 2025 database. Using the screener, we compiled a list of US stocks with a market cap over $2 billion, a 3-year revenue growth rate of at least 20%, and analyst coverage from at least three analysts. Next, we ranked the stocks in ascending order of upside percentage. We have also included the number of hedge funds holding the stock, based on Insider Monkey’s hedge fund database, which tracks 978 stocks as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
13. TG Therapeutics Inc (NASDAQ:TGTX)
Price Target Upside: 75.33%
Number of Hedge Fund Holders: 37
TG Therapeutics Inc. (NASDAQ:TGTX) is one of the best revenue growth stocks to buy right now.
On February 2, JPMorgan analyst Brian Cheng reduced the price target on TG Therapeutics to $46 from $49 while maintaining the Overweight rating on the shares. The investment bank had recently updated the model on the company.
TG Therapeutics is set to present its trial results on February 6 at a medical forum in San Diego, California. The presentation will focus on the results of its Briumvi treatment for relapsing multiple sclerosis in adults.
Earlier, in mid-January, H.C. Wainwright analyst Emily Bodnar gave a Buy rating on the stock, citing the company’s strong commercial momentum and anticipated clinical catalysts in 2026. These include results for consolidated IV dosing and self-administered subcutaneous formulation for Briumvi, which could boost its market share against competing therapies.
On January 29, TD Cowen analyst Tara Bancroft reiterated a Buy rating on TG Therapeutics and set a $50 price target.
TG Therapeutics Inc. (NASDAQ:TGTX) is a biopharmaceutical company engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
12. Intapp Inc (NASDAQ:INTA)
Price Target Upside: 76.73%
Number of Hedge Fund Holders: 28
Intapp Inc (NASDAQ:INTA) is one of the Best Revenue Growth Stocks to Buy Right Now.
On February 4, Intapp saw its stock price target reduced by a number of firms. Truist lowered the price target on the stock to $35 from $68, BofA to $50 from $76, UBS to $54 from $62, Stifel to $40 from $50, and JPMorgan to $58 from $70.
Intapp had reported its Q2 results a day earlier on February 2. The company’s Q2 EPS was $0.33, exceeding the consensus of $0.26, while revenue was $140.2 million, beating the consensus of $138.2 million. The quarter’s results were supported by the addition of new clients and the expansion of existing client accounts, according to Intapp CEO John Hall. “Our results reflect our proficiency in serving enterprise clients, our growing partner ecosystem, and demand for our new AI-driven solutions in the highly-regulated industries we serve,” he said.
Intapp’s board said it authorized a common stock repurchase program of up to $200 million. The share repurchase program follows the $150.0 million share repurchase program previously authorized in August 2025, which has been completed.
Intapp, Inc. is a software company that provides IT services and industry-specific, cloud-based solutions for the global professional and financial services industry.
